대한뉴팜

Daehan New Pharm, together with Semyung University and the University of Suwon, has been awarded the bid for the land (E5-1 block) in Pangyo’s 2nd Techno Valley through an industry-academia-research consortium established for mutual growth. On the acquired land, an Industry-Academia-Research R&D Center with five underground floors, ten above-ground floors, and a total floor area of 9,237 m² (2,794 pyeong) is planned to be constructed, with occupancy scheduled for the end of 2020. To strengthen R&D capabilities, the consortium plans to strategically build a joint research and information exchange hub, establishing a connected system from basic research to commercialization and global market development. Furthermore, the center will provide practical training venues and opportunities for university students, open spaces for academic seminars and educational programs, and create synergy among academic, industrial, and research institutions. Specifically, within the Industry-Academia-Research Center, a Central Research Institute and Bio Research Laboratory will be established, along with Semyung University’s Clinical Trial Center for Bio-Oriental Medicine Industry and the University of Suwon’s Beauty Science Research Center, creating an integrated system for mutual growth. Research to be conducted here will include preclinical and clinical studies, skin stem cell research, development of functional oriental materials, and efficacy verification for cosmetic and pharmaceutical applications through optimized formulation R&D. The industry-academia-research collaboration will operate organically to swiftly commercialize research achievements.

Daehan New Pharm has launched a new product, “Super Neofen”, developed to address swine pleuropneumonia, a contagious livestock disease. Swine pleuropneumonia, which frequently occurs during the winter season, is a bacterial infection that causes considerable damage to pig farms worldwide and has until now relied primarily on vaccination for prevention. Following years of research, “Super Neofen”, a newly developed therapeutic agent, has completed new drug registration with the Animal and Plant Quarantine Agency after passing safety and efficacy verification through domestic clinical trials. “Super Neofen” is a medication that strengthens the immune system to fight against Actinobacillus pleuropneumoniae, the causative agent of swine pleuropneumonia. It is a specialized treatment combining three active ingredients—Florfenicol, an antibiotic effective for respiratory diseases in pigs; Acetaminophen, providing antipyretic, analgesic, and anti-inflammatory effects; and Bromhexine, acting as an antitussive and expectorant. This combination delivers rapid therapeutic effects for both acute and chronic respiratory conditions. Clinical and field trials in domestic farms have shown that while the antibacterial activity of “Super Neofen” was similar to single-agent Florfenicol products, the treatment period was significantly shorter when administered compared to other formulations. The product allows simultaneous administration of the three components, making it more convenient, economical, and efficient for farmers by improving treatment outcomes, reducing labor, and enhancing productivity. Starting this month, Daehan New Pharm will begin full-scale distribution of “Super Neofen” and expand its domestic supply network aggressively. The product’s composition patent (Application No. 10-2017-0058616) has been successfully filed, and global market entry is planned for countries including the United States, China, and Russia.

Tambutin Tablet (export name: Trimedat) wereed as one of the Top 3 Best Drugs in the Antispasmodic category for the second consecutive year at the Russian Pharma Awards ceremony held last month in Moscow, Russia. The Top 3ion was determined through anonymous voting by over 500,000 medical professionals registered on “Doctor at Work,” the largest professional network in Russia. The award carries special significance as the evaluation is made objectively by local healthcare specialists who assess the convenience and efficacy of pharmaceutical products. Tambutin Tablet (Trimebutine Maleate) are a convenient gastrointestinal motility regulator with various therapeutic benefits, restoring the normal physiological activity of muscles in different parts of the digestive tract. The product is on track to achieve annual sales of 5 billion KRW in Russia alone. To further enhance brand awareness, Daehan New Pharm launched a large-scale advertising campaign in October across online platforms and ten regional TV stations in Russia, including Channel One. The TV commercial, centered around the concept “smooth digestive rhythm like music,” metaphorically expresses the harmony of well-functioning digestive organs through the harmony of music, receiving highly positive feedback from local audiences. By earning continued recognition for its product excellence from both doctors and patients in Russia and maintaining active promotional efforts, the company aims to strengthen brand recognition and consumer engagement. For 2018, Daehan New Pharm has set a goal of achieving Top 3 Best Drug recognition for the third consecutive year and exceeding a 40% year-on-year sales growth target.

Tambutin Tablet are on track to achieve annual sales of 5 billion KRW in Russia. The export formulation, Tambutin Tablet (Trimebutine Maleate), is a gastrointestinal motility regulator known for its versatile therapeutic effects, including restoring the normal physiological activity of muscles in various parts of the digestive tract. Last year, the product was recognized as an outstanding pharmaceutical at the Russian Pharma Awards, whichs winners based on votes from Russian physicians. In Russia, Tambutin Tablet will also be featured in a nationwide TV advertising campaign starting in December—an uncommon distinction for over-the-counter medicines—indicating strong brand momentum and projecting over 40% sales growth in the coming year. Following the success of Tambutin Tablet, Daehan New Pharm has continued to achieve solid performance by completing product registrations for injectable formulations, antibiotics, and oral medications. Leveraging successful exports to Russia and its robust portfolio of wellness-oriented pharmaceuticals, the company has expanded into Central Asian markets such as Mongolia and Kazakhstan this year. From next year, Daehan New Pharm plans to strengthen its export growth further as product registrations are completed in key Southeast Asian markets, including the Philippines, Taiwan, and Vietnam.

The company announced on July 13 the results of a comprehensive corporate tax investigation through an official disclosure and completed the full payment of corporate tax amounting to 15.67 billion KRW on July 31. After completing the tax payment, the company plans to file an appeal and a petition for review in accordance with the Framework Act on National Taxes. Taking this integrated tax audit as an opportunity, Daehan New Pharm is pursuing greater internal soundness by innovating its management systems and focusing on research and development. The company’s sales grew by 7.8% in 2012 and 18.1% in 2013, maintaining an impressive annual growth rate of over 20% for three consecutive years starting in 2014. This strong growth has been driven by a well-structured product portfolio and differentiated therapeutic solutions that established Daehan New Pharm as a leader in the obesity and wellness pharmaceutical segments. In addition, continuous R&D efforts have enabled the company to expand its product lines into chronic disease treatments such as hypertension and hyperlipidemia. Since 2013, the company has also been investing aggressively in biotechnology, establishing a serum-free culture medium production facility in the Hyangnam Pharmaceutical Complex to provide customized media to clients. The company’s Central R&D Center in Hyangnam and its affiliated research institute in Osong are collaborating closely to carry out various bio-research projects. Daehan New Pharm’s focus on biotechnology stems from its strategy to combine its established strengths in obesity and wellness pharmaceuticals with the bio sector, thereby creating business synergy and new growth engines for the future. To further strengthen sales and R&D, the company continues to steadily expand its recruitment each year. Notably, all 341 employees at Daehan New Pharm are full-time regular employees—a policy aligned with the company’s management philosophy of fostering a “warm and inclusive workplace.” Every member of the organization is dedicated to sustaining the company’s strong growth trajectory and will continue to drive the momentum of innovation that has been built over the years.

Daehan New Pharm has recorded a 23% year-over-year growth rate in the obesity treatment market, continuing to strengthen its leadership position. The company has achieved sustained annual sales growth of over 20% for the past three years, driven by the continued launch of reimbursable products, increased market share of oral obesity drugs, and expansion into the non-reimbursable injectable treatment segment. Among these, oral obesity drugs have shown particularly steady growth. Daehan New Pharm’s representative oral anti-obesity products include appetite suppressants such as Phentin (Phendimetrazine), Phestin (Phentermine), and Phtym (Phentermine HCl), as well as the fat absorption inhibitor Zerofat (Orlistat), which the company co-markets with Mothers Pharmaceutical. In addition, Daehan New Pharm offers a wide range of obesity-related therapeutic products, collectively accounting for over 40% of the anti-obesity drug market share. Following a decline in obesity surgeries such as gastric banding and sleeve gastrectomy after the Shin Hae-chul incident, interest in combined pharmacological and exercise-based therapies has grown. As a result, the oral obesity drug market has steadily expanded, reaching approximately 100 billion KRW in 2016 according to IMS data, and continues to show growth momentum. Although newer drugs such as Belviq (Ildong Pharmaceutical) and Contrave (Kwangdong Pharmaceutical) have contributed to market expansion, traditional appetite suppressants containing phendimetrazine or phentermine and fat absorption inhibitors still hold a dominant share of the obesity market. Utilizing its extensive experience in obesity prescription marketing, Daehan New Pharm continues to expand its trading network and revenue. The company has also developed therapeutics to alleviate side effects associated with oral obesity medications, driving rapid sales growth. In the first half of this year, Daehan New Pharm’s oral obesity drug sales achieved an impressive 23% increase compared to the same period last year. Moving forward, the company plans to further strengthen brand recognition for products such as Phentin, Fastin, and Topin and expand its market share through its 3S strategy—self-control, self-confidence, and satisfaction—designed to meet the needs of both customers and patients.

Daehan New Pharm has launched its newly redesigned website on the 6th. In response to the steady increase in website traffic driven by the company’s continuous sales growth, Daehan New Pharm carried out a renewal project to make the website more accessible, convenient, and user-friendly. In the renewal, the product categories have been reorganized into four main sections—Human Pharmaceuticals, Veterinary Pharmaceuticals, Biopharmaceuticals, and Export Pharmaceuticals—allowing visitors to easily browse Daehan New Pharm’s product lineup. Additionally, a new communication feature has been introduced, enabling customer inquiries to be directly forwarded in real time to the responsible departments for prompt responses. The company also plans to sequentially launchd versions of its mobile and English websites in the near future.

The company’s newly launched non-reimbursable injectable products have successfully established a firm position in the market, becoming a key driver of new revenue growth. In April of last year, Daehan New Pharm launched “New-DN Injection” formulated with Polydeoxyribonucleotide (commonly known as the salmon DNA ingredient). Later, in December, the company signed an exclusive sales agreement with HaspiCare Co., Ltd. to distribute the mistletoe injection “Iscador (ISCADOR).” “New-DN Injection” is primarily used in departments such as anesthesiology and pain medicine, orthopedics, and dermatology as an adjunct therapy for pain treatment and aesthetic procedures. “Iscador,” an immune-boosting mistletoe extract used as an anticancer adjuvant, is mainly administered in convalescent hospitals and oncology clinics. Although the non-reimbursable nutritional injection market has stagnated due to oversupply following the release of generic products, Daehan New Pharm has continued to expand and restructure its portfolio by diversifying into new therapeutic areas such as pain relief and anticancer adjuvant treatments. In addition, in April this year, the company began exclusive domestic sales of HA fillers—“Qugel,” “Flore,” and “Cheongaan”—manufactured by Korea BNC Co., further expanding its reach into the filler market. Among its 30 non-reimbursable injectable products, the newly introduced “New-DN Injection” “Iscador,” and HA filler lines have achieved a combined 30% share of total injectable sales within just one year of launch. As the non-reimbursable injection market continues to evolve, Daehan New Pharm plans to lead market transformation by continuously introducing differentiated and innovative new products.

Daehan New Pharmed by global veterinary vaccine leader HIPRA for its strong cattle product sales network in Korea - The only bovine mastitis vaccine registered with the European Medicines Agency (EMA), proven for safety and efficacy, providing dual protection against two major pathogens - “A significant contribution to preventing chronic dairy farm diseases and advancing Korea’s veterinary and dairy industries” Daehan New Pharm has signed an exclusive sales agreement with global veterinary vaccine company HIPRA for “Hipra Startvac,” a multivalent vaccine developed to combat bovine mastitis, and has commenced product distribution in Korea. Through this partnership, Daehan New Pharm will begin full-scale domestic supply of “Hipra Startvac,” targeting bovine mastitis—a chronic, recurring disease in dairy farms. “Hipra Startvac” prevents infection caused by Staphylococcus aureus and Escherichia coli, the two major pathogens responsible for bovine mastitis. As the first bovine mastitis vaccine approved by the European Medicines Agency (EMA), it has been verified for both safety and efficacy and is currently registered and sold in over 50 countries worldwide. No side effects such as abscess formation or somatic cell count increases have been reported, and clinical trials conducted on local dairy farms in Gyeonggi Province confirmed an absence of adverse reactions. Polysaccharide biofilms formed by Staphylococcus aureus and coagulase-negative staphylococci (CNS) enable bacteria to adhere to mammary glands, inducing antibiotic resistance and high pathogenicity. “Hipra Startvac” is the only vaccine proven to inhibit and prevent this biofilm formation, thereby suppressing bacterial proliferation and neutralizing adhesion factors to effectively prevent mastitis. Unlike existing domestic competitors, “Hipra Startvac” provides cross-protection not only against S. aureus and E. coli but also against CNS and coliform bacteria—making it a truly multivalent vaccine. The total Korean vaccine market is estimated at approximately 300 billion KRW, with foreign companies accounting for 60–70% of the domestic livestock vaccine segment. This exclusive sales agreement marks Daehan New Pharm’s first entry into the vaccine market, and with its strong presence in the cattle segment, the company anticipates sustained growth in mastitis vaccine sales. Unlike conventional vaccines, “Hipra Startvac” has no post-injection side effects and is recommended for use even during lactation. The optimal vaccination schedule involves intramuscular injection in the neck 45 and 10 days before calving and at 50 days after calving, effectively reducing the risk of infection, economic losses, and mastitis incidence. Kim Myung-hwi, Head of HIPRA Korea, stated, “We are delighted to grant Daehan New Pharm exclusive distribution rights for ‘Hipra Startvac,’ a vaccine with exceptional efficacy compared to competitors. Daehan New Pharm’s strong nationwide distribution network for cattle products played a key role in our decision. We hope this vaccine will help establish a preventive dairy farming culture in Korea and serve as a definitive solution to mastitis, a chronic challenge for dairy producers.” Following this agreement, Daehan New Pharm plans to collaborate with HIPRA headquarters to provide on-site bacterial diagnostic systems and related services for dairy farms seeking to implement advanced diagnostic infrastructures.